UPDATE 2-Data from Anacor's nail infection drug disappoints; shares down

Tue Jan 29, 2013 11:14am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

* Drug meets main and secondary goals

* Results less impressive than those of competing drug

* Anacor to file for U.S. approval in mid-2013

* Shares down as much as 24 pct (Adds details, analyst comments, updates stock movement)

By Pallavi Ail

Jan 29 (Reuters) - Anacor Pharmaceuticals' experimental drug for treating fungal infection of the nails showed it can cure the disease, but the results fell short of those from a competing drug from Valeant Pharmaceuticals International Inc .

Anacor shares fell 24 percent to $3.95 on the Nasdaq, their lowest in almost one-and-a-half years, before recovering to $4.17, but were still down 19 percent.

Anacor said on Tuesday that 6.5 percent patients treated with its drug tavaborole experienced a complete cure, compared with 0.5 percent of patients on a placebo.

Data released by Valeant in November showed that its drug efinaconazole completely cured 17.8 percent of patients, compared with 3.3 percent of those receiving a placebo.   Continued...